key: cord-0750258-2b2yf4b4
authors: Masuccio, Fabio Giuseppe; Re, Marianna Lo; Bertolotto, Antonio; Capobianco, Marco; Solaro, Claudio
title: Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment
date: 2020-10-21
journal: Mult Scler Relat Disord
DOI: 10.1016/j.msard.2020.102592
sha: 6ba19e2d3b11d9dac5de9c571d5f06c2dc428558
doc_id: 750258
cord_uid: 2b2yf4b4

Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) represents a demyelinating disorder for which tocilizumab, an anti-IL6 receptor, has been tested to prevent disabling relapses. In a subgroup of patients affected with novel Coronavirus disease (COVID-19), tocilizumab has also increased the survival rate. We present the case of a 31-years-old Caucasian patient who experienced an almost asymptomatic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection during treatment with tocilizumab, which was continued due to the very high risk of relapses of the patient. According to this case, tocilizumab might be not discontinued during COVID-19.

Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) represents a demyelinating disorder for which tocilizumab, an anti-IL6 receptor, has been tested to prevent disabling relapses.

In a subgroup of patients affected with novel Coronavirus disease , tocilizumab has also increased the survival rate. We present the case of a 31-years-old Caucasian patient who experienced an almost asymptomatic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection during treatment with tocilizumab, which was continued due to the very high risk of relapses of the patient. According to this case, tocilizumab might be not discontinued during COVID-19.

Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease (MOGAD) represents a demyelinating disorder characterized by attacks of optic neuritis (ON) and/or episodes of myelitis (Wynford-Thomas et al., 2019) . Antibodies to MOG (MOG-Abs) have consistently been identified in several demyelinating syndromes and between them in adults affected with Aquaporin-4 seronegative Neuromyelitis Optica spectrum disorder (Jarius et al., 2016) .

Several therapies have been tested in order to prevent the potentially disabling relapses in MOGAD and among them the anti-IL-6 receptor tocilizumab has been newly introduced (Whittam et al., 2020) . During the recent pandemy of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), this monoclonal antibody has also represented an alternative treatment for a sub-group of patients affected with novel Coronavirus disease (COVID-19) (Toniati et al., 2020) .

We describe a case of a 31-year-old Caucasian woman who had a history of paraesthesias in the left upper limb occurred in 2009. In 2014 she experienced an episode of left ON and was diagnosed with multiple sclerosis due to clinical and brain Magnetic Resonance Imaging (MRI) findings.

Therefore, subcutaneous Interferon-1 every-other-day was started. It is important to note that while the patient was in treatment with tocilizumab, she experienced an almost asymptomatic SARS-CoV-2 infection (confirmed by two positive swabs) and did not need any intervention or hospitalization. Furthermore, her clinical situation, characterized by paraparesis with a Medical Research Council strength 3/5, and an Expanded Disability Status Scale of 6.5, was not modified, maintaining her own walking ability.

COVID-19 might provoke a cytokine-mediated hyperinflammatory syndrome with rapid onset of respiratory failure and tocilizumab improved survival rate in critically compromised COVID-19 patients (Capra et al., 2020) . A purely speculative question arises also on the potential beneficial effect of this anti-IL6 receptor in demodulating a potentially devastating viral infection in a patient with an immuno-mediated condition such as MOGAD.

When considering this single case, it might be deemed that tocilizumab might be not discontinued also during SARS-CoV-2 infection, in particular in a very "active" subject who experienced two previous myelitis and failed Rituximab therapy, in fact being at very high risk of relapses, potentially induced by the cytokine storm deriving from COVID-19.

Another consideration should be done, i.e. if this might have been in any case an almost asymptomatic infection regardless of treatment and primary disease. At the moment, however, the answer to these issues cannot be given and further studies should be performed also in individuals affected by these demyelinating diseases.

Informed Consent: Written informed consent was collected from the patient for the inclusion of anonymized clinical data in a scientific publication

Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia

MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A

Neurological update: MOG antibody disease